Cancer drug safety tracked in real patients
NCT ID NCT04328662
Summary
This study monitored the safety of Ninlaro (ixazomib) when used to treat multiple myeloma in real-world medical practice in China. Researchers followed 482 patients with multiple myeloma who were already taking or about to start Ninlaro treatment. The goal was to collect information about side effects and treatment outcomes outside of controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Jining Medical College
Jining, Shandong, 272007, China
-
Anhui Cancer Hospital
Hefei, Anhui, 230031, China
-
Beijing Chao-yang Hospital,Capital Medical University
Beijing, Beijing Municipality, 100020, China
-
Beijing Chao-yang Hospital,Capital Medical University(Shijingshan)
Beijing, Beijing Municipality, 100043, China
-
Beijing Jishuitan Hospital
Beijing, Beijing Municipality, 100035, China
-
Datong Third People's Hospital
Datong, Shanxi, 037046, China
-
Hainan General Hospital
Haikou, Hainan, 570311, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450003, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
-
Shanxi Provincial People's Hospital
Taiyuan, Shanxi, 030012, China
-
Shaoxing People's Hospital
Shaoxing, Zhejiang, 312099, China
-
Soochow Hongci Blood Disease Hospital
Suzhou, Jiangsu, 215100, China
-
Sun Yat-Sen Memorial Hospital
Guangzhou, Guangdong, 510120, China
-
Tai'an Central Hospital
Tai’an, Shandong, 271099, China
-
Taizhou First People's Hospital
Taizhou, Zhejiang, 318020, China
-
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, 116011, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Bethune Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110001, China
-
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510630, China
-
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
-
Wuxi People's Hospital
Wuxi, Jiangsu, 214023, China
-
Zhabei Central Hospital, Jing'an District, Shanghai
Shanghai, Shanghai Municipality, 200070, China
-
Zhujiang Hospital, Southern Medical University
Guangzhou, Guangdong, 510280, China
Conditions
Explore the condition pages connected to this study.